about
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingMicroRNAs in lipid metabolismAntagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosismicroRNAs and cholesterol metabolismCD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimerHow Biomaterials Can Influence Various Cell Types in the Repair and Regeneration of the Heart after Myocardial InfarctionExtracellular communication via microRNA: lipid particles have a new messageCD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsPre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteriesHDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells.Chronic over-expression of heat shock protein 27 attenuates atherogenesis and enhances plaque remodeling: a combined histological and mechanical assessment of aortic lesionsMicroRNA control of high-density lipoprotein metabolism and functionInhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.Macrophage Mitochondrial Energy Status Regulates Cholesterol Efflux and Is Enhanced by Anti-miR33 in Atherosclerosis.Local Anti-miR Delivery: The Latest in the Arsenal of Drug-Eluting Stents.Therapeutic Inhibition of miR-33 Promotes Fatty Acid Oxidation but Does Not Ameliorate Metabolic Dysfunction in Diet-Induced Obesity.MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosisThe plaque "micro" environment: microRNAs control the risk and the development of atherosclerosis.The role of microRNAs in cholesterol efflux and hepatic lipid metabolism.Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retentionmiRNA Targeting of Oxysterol-Binding Protein-Like 6 Regulates Cholesterol Trafficking and EffluxMycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism.Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis.Hypoxia induces netrin-1 and Unc5b in atherosclerotic plaques: mechanism for macrophage retention and survivalNetrin-1 promotes adipose tissue macrophage retention and insulin resistance in obesity.Heat shock protein 27: clue to understanding estrogen-mediated atheroprotection?MicroRNAs in cardiovascular health: from order to disorder.Unlocking the door to new therapies in cardiovascular disease: microRNAs hold the key.MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution.MicroRNAs regulate the immunometabolic response to viral infection in the liver.microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis.Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis.Macrophage miRNAs in atherosclerosis.The walking dead: macrophage inflammation and death in atherosclerosis.MicroRNAs in the Pathobiology and Therapy of Atherosclerosis.Cell Death in the Vessel Wall: The Good, the Bad, the Ugly.Serum heat shock protein 27 levels represent a potential therapeutic target for atherosclerosis: observations from a human cohort and treatment of female mice.MiR-33 contributes to the regulation of cholesterol homeostasis.Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a
P50
Q24627398-94346B4E-28E5-441C-8967-6A9C94FE2D97Q24633633-34876D7A-21FD-43F5-B0CD-5FDB37789F7EQ24634165-2DC0A11F-095A-4BEC-97DC-AA1CC71B0917Q24634470-40A1EF22-CDE2-4EF9-AF34-499029ADBC63Q24642646-ADCCD5F7-3219-4D4D-80F4-BF5944D36579Q26739723-E90F02B6-6D4E-4734-87A0-735907F2639BQ27010226-A79D5F31-3F16-4C84-A9F2-DDAE3D44EE20Q28506984-C1609F5D-ECCF-4106-89AF-FF088028DED6Q29615704-CCCE3DFE-7F4B-4F75-BBD0-C28571C1F08CQ33808599-58152D0F-EB58-49E1-B41B-2193FE555724Q33868782-F578AC2C-BC24-48D2-9600-7A6DF973E6AAQ34586387-DDD2E2F5-1FA3-4A58-802F-C150828579BDQ35200081-36980CF4-502E-471B-827C-2A216BFEBBE9Q35606800-6CAE0993-DC12-409C-88A3-FB713B6DE1D6Q36083076-A042C28A-D6AB-433C-82A9-A8507CACC6E0Q36198491-1B59D748-E6AB-406C-A38F-261AA720FCAEQ36326825-0D838D5F-33A6-4F60-A9D1-6E73A410B092Q36335947-BF256E9D-C29E-406B-B719-39E3EF5BBD5FQ36526198-7CC35E1C-8647-4840-90AB-1A8CEFCBA445Q36728983-E163539C-80E1-4FC6-9AC6-9EDFA235812DQ36824150-A6D4DAB7-1417-426D-B8AF-1725FD64D1EDQ36849588-ED38DBDD-A53C-45E6-B332-4D8D2EFAADC7Q36917989-DCA59E02-EE16-4D8D-A15B-5B7E02DB1F63Q37175720-49329C36-554A-4C18-B0F9-9F976B022D2AQ37222761-1E64F906-EC26-44A2-B3C4-AA1BAAEFCD78Q37695058-A53BA23F-54A2-42BA-AC39-A3554959AA08Q37775329-6085C38D-0EF6-47FF-85F8-488BC8C632B8Q38134561-84BBFD8F-954D-421A-9A67-8447F954BCD8Q38258936-B3C87258-A258-4803-B5DD-56381CA0883AQ38292581-BA661BCB-C189-4001-99A5-357AC7DC72B3Q38826844-509CDAF7-3395-4A79-9454-E88A8B6145B0Q38827780-A278A851-9F06-4527-A27C-2A807ECFE421Q38828033-DD2124C2-AB6C-41B9-A7DB-4D88D7ADB09CQ38905337-60B2D876-E74C-496B-8CA6-E30AD77947ACQ39109119-567F0409-63C1-4EAB-9433-44B172A886A7Q39148384-BA5B55BC-0684-4EB6-9FD9-E4F637186653Q39388843-858646D3-CBF5-42A6-829A-9A38C01066D3Q39402712-EDF3BCF9-440E-478C-8075-CECA3E765D1AQ39704194-A3EAEC07-4E19-4E29-B8D2-64173C0D91C1Q41239832-0DA1E190-AF4F-4A9C-988B-1F186779BE86
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katey Rayner
@ast
Katey Rayner
@en
Katey Rayner
@es
Katey Rayner
@nl
Katey Rayner
@sl
type
label
Katey Rayner
@ast
Katey Rayner
@en
Katey Rayner
@es
Katey Rayner
@nl
Katey Rayner
@sl
prefLabel
Katey Rayner
@ast
Katey Rayner
@en
Katey Rayner
@es
Katey Rayner
@nl
Katey Rayner
@sl
P106
P1153
9250280000
P21
P31
P496
0000-0001-6230-426X